Merck to Acquire Prometheus Biosciences for $10.8 Billion

On 16th April 2023, Merck, a leading biopharmaceutical company, announced that it has agreed to acquire Prometheus Biosciences for $10.8 billion, in a move to strengthen its presence in the field of immunology.